Novel Mannich Bases Derived from 2-Substituted Benzimidazole and (Thio)Hydantoin Moieties as Potent Histone Deacetylase 6 (HDAC6) Inhibitors

Document Type : Original research articles

Authors

Department of Pharmaceutical Medicinal Chemistry and Drug Design, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt

Abstract

Novel Mannich bases derived from 2-substituted benzimidazole and (thio) hydantoin moieties, were synthesized as histone deacetylase 6 (HDAC6) inhibitors with potential cytotoxic activity. All derivatives were tested In vitro against HDAC6 enzyme. IR, 1H NMR, 13C NMR and mass spectroscopy confirmed the structure of synthesized compounds. All tested compounds significantly inhibited HDAC6 at nanomolar level. Compound 2c was the most potent presenting significant HDAC6 inhibitory activity (IC50 = 97.356± 5.7 nM), nearly equipotent to SAHA reference drug (IC50 = 91.732 ± 5.4 nM). In vitro cytotoxicity study was also carried out. Compound 2c exhibited potent cytotoxic activity against the tested cells (CCRF-CEM and MOLT-4) showing one digit micromolar IC50s. Compound 2c (IC50 = 3.66±0.22 uM) was 2-fold more active than SAHA reference drug (IC50 = 6.8±0.41 uM) against MOLT-4 cell line. Furthermore, a docking study demonstrated the ability of target Mannich bases to achieve an excellent fitting inside the binding site of HDAC6 enzyme.

Keywords

Main Subjects

Azhar International Journal of Pharmaceutical and Medical Sciences
Volume 1, Issue 3
The articles belongs to the special issue selected papers from Azhar 2nd International Conference of Pharmaceutical and Medical Sciences (2021)
November 2021
Pages 66-74

Files

Share

How to cite

Statistics